Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency for the Treatment and Reduction of Acne Scarring
Phase: NA
Conditions: Acne Scars - Mixed Atrophic and Hypertrophic
Sponsor: Venus Concept

 
CONFIDENTIAL 
This document is strictly confidential.  It was developed by Venus Concept Inc. and should not be disclosed to a third party, with the exception  of regulatory agencies and study  
audit personnel. Reproduction, modification or adaptation, in part or in total, is strictly forbidden without prior written  approval by Venus Concept Inc. 
Throughout this document, symbols indicating proprietary names (®, TM) are not displayed. The appearance of product names without these symbols does not imply that these  
names are not protected. 
 
Clinical Evaluation of the Safety and Performance of 
Fractional Radiofrequency for the Treatment and 
Reduction of Acne Scarring 
 
STUDY SPONSOR 
Venus Concept Inc. 
SPONSOR ADDRESS 
235 Yorkland Blvd., Suite 900 
Toronto, ON M2J 4Y8 
Canada 
STUDY NUMBER 
VI0121 
TEST PRODUCT 
Venus VivaMD 
PRINCIPAL 
INVESTIGATOR 
Dr. Neil Sadick 
PROTOCOL 
VERSION 
1.0 
PROTOCOL DATE 
29th January 2021 
 
 
 
 
 
 

CLINICAL STUDY 
PROTOCOL 
 
VI0121 
Venus VivaMD 
 
Venus Concept    
CONFIDENTIAL 
Page 3 of 40 
     1.0  
January 29th, 2021 
 
Table of Contents 
PROTOCOL VERSION CONTROL ........................................................................................................... 2 
sponsor approval/signature page ................................................................................................................... 6 
principal investigator approval/signature page ............................................................................................. 7 
LIST OF ABBREVIATIONS ....................................................................................................................... 8 
STUDY SUMMARY .................................................................................................................................... 8 
SCHEMATIC OF STUDY DESIGN ......................................................................................................... 10 
1 
KEY ROLES ................................................................................................................................... 10 
2  
INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE ........ 11 
2.1 
Background Information ........................................................................................................ 11 
2.2 
Rationale ................................................................................................................................ 12 
2.3 
Potential Risks and Benefits .................................................................................................. 12 
2.3.1 
Known Potential Risks ......................................................................................... 12 
2.3.2 
Known Potential Benefits .................................................................................... 12 
3 
OBJECTIVES AND PURPOSE ..................................................................................................... 13 
4 
STUDY DESIGN AND ENDPOINTS ........................................................................................... 13 
4.1 
Description of the Study Design ............................................................................................ 13 
4.2.1 
Primary Endpoint ................................................................................................. 13 
4.2.2 
Secondary Endpoints ........................................................................................... 13 
4.2.3 
Exploratory Endpoints ......................................................................................... 13 
5 
STUDY ENROLLMENT AND WITHDRAWAL ......................................................................... 13 
5.1 
Participant Inclusion Criteria ................................................................................................. 13 
5.2 
Participant Exclusion Criteria ................................................................................................ 14 
5.3 
Strategies for Recruitment and Retention .............................................................................. 14 
5.4 
Participant Withdrawal or termination .................................................................................. 15 
5.4.1 
Reasons for Withdrawal or Termination .............................................................. 15 
5.4.2 
Handling of Participant Withdrawals or termination ........................................... 15 
5.5 
Premature Termination or Suspension of Study .................................................................... 15 
6 
INVESTIGATIONAL DEVICE ..................................................................................................... 16 
6.1 
Investigational device and Control Description ..................................................................... 17 
6.1.1 
Acquisition ........................................................................................................... 17 
6.1.2 
Device Specific Considerations ........................................................................... 17 
6.2 
Investigational device Accountability Procedures ................................................................. 17 
7.1 
Study Procedures/Evaluations ............................................................................................... 17 
7.1.1 
Study specific procedures .................................................................................... 17 
7.2 
Laboratory Procedures/Evaluations ....................................................................................... 17 
7.2.1 
Clinical Laboratory Evaluations .......................................................................... 18 
7.3 
Study Schedule ...................................................................................................................... 18 
7.3.2 
Enrollment/Baseline/SCREENING ..................................................................... 18 
7.3.2 
Baseline Visit ....................................................................................................... 18 
7.3.3 
Treatment Visits ................................................................................................... 19 
7.3.3 
Follow-up ............................................................................................................. 21 

CLINICAL STUDY 
PROTOCOL 
 
VI0121 
Venus VivaMD 
 
Venus Concept    
CONFIDENTIAL 
Page 4 of 40 
     1.0  
January 29th, 2021 
 
7.3.5 
Early Termination Visit ....................................................................................... 21 
7.3.7 
Schedule of Events Table .................................................................................... 21 
7.4 
Justification for Sensitive Procedures .................................................................................... 22 
7.5 
Concomitant Medications, Treatments, and Procedures........................................................ 22 
7.6 
Prohibited Medications, Treatments, and Procedures ............................................................ 22 
7.7 
Prophylactic Medications, Treatments, and Procedures ........................................................ 23 
7.8 
Rescue Medications, Treatments, and Procedures ................................................................. 23 
8 
ASSESSMENT OF SAFETY ......................................................................................................... 23 
8.1 
Specification of Safety Parameters ........................................................................................ 23 
8.1.1 
Definition of Adverse Events (AE)...................................................................... 23 
8.1.2 
Definition of Serious Adverse Events (SAE) ...................................................... 24 
8.1.3 
Definition of Unanticipated Problems (UP) ........................................................ 24 
8.1.4 
Definition of Device deficiency ........................................................................... 24 
8.2 
Classification of an Adverse Event ........................................................................................ 25 
8.2.1 
Severity of Event ................................................................................................. 25 
8.2.2 
Relationship to Study Agent ................................................................................ 25 
8.2.3 
Expectedness ........................................................................................................ 26 
8.3 
Time Period and Frequency for Event Assessment and Follow-Up ...................................... 26 
8.4 
Reporting Procedures ............................................................................................................. 27 
8.4.1 
Adverse Event Reporting ..................................................................................... 27 
8.4.2 
Serious Adverse Event Reporting ........................................................................ 27 
8.4.5 
Reporting of Pregnancy ....................................................................................... 28 
8.5 
Study Halting Rules ............................................................................................................... 28 
8.6 
Safety Oversight .................................................................................................................... 28 
9 
CLINICAL MONITORING ............................................................................................................ 28 
10 
STATISTICAL CONSIDERATIONS ............................................................................................ 29 
10.1 
Statistical and Analytical Plans.............................................................................................. 29 
10.2 
Statistical Hypotheses ............................................................................................................ 29 
10.3 
Analysis Datasets ................................................................................................................... 29 
10.4 
Description of Statistical Methods ......................................................................................... 30 
10.4.1 
General Approach ................................................................................................ 30 
10.4.2 
Analysis of the Primary Efficacy Endpoint(s) ..................................................... 30 
10.4.3 
Analysis of the Secondary Endpoint(s)................................................................ 31 
10.4.4 
Safety Analyses.................................................................................................... 31 
10.4.5 
Adherence and Retention Analyses ..................................................................... 32 
10.4.6  
Baseline Descriptive Statistics ............................................................................. 33 
10.4.7 
Planned Interim Analyses .................................................................................... 33 
10.4.10 
Tabulation of Individual Response Data.............................................................. 33 
10.5 
Measures to Minimize Bias ................................................................................................... 33 
10.5.1 
Enrollment/ Randomization/ Masking Procedures .............................................. 33 
10.5.2 
Evaluation of Success of Blinding ....................................................................... 33 
11 
SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS ......................... 34 

CLINICAL STUDY 
PROTOCOL 
 
VI0121 
Venus VivaMD 
 
Venus Concept    
CONFIDENTIAL 
Page 5 of 40 
     1.0  
January 29th, 2021 
 
12 
QUALITY ASSURANCE AND QUALITY CONTROL .............................................................. 34 
13 
ETHICS/PROTECTION OF HUMAN SUBJECTS ....................................................................... 35 
13.1 
Ethical Standard ..................................................................................................................... 35 
13.2 
Institutional Review Board .................................................................................................... 35 
13.3 
Informed Consent Process ..................................................................................................... 35 
13.3.1 
Consent/assent and Other Informational Documents Provided to Participants ... 35 
13.3.2 
Consent Procedures and Documentation ............................................................. 35 
13.4 
Participant and data Confidentiality ...................................................................................... 36 
13.4.1 
Research Use of Stored Human Samples,Specimens or Data ............................. 36 
13.5 
Future Use of Stored Specimens ............................................................................................ 37 
14 
DATA HANDLING AND RECORD KEEPING ........................................................................... 37 
14.1 
Data Collection and Management Responsibilities ............................................................... 37 
14.2 
Study Records Retention ....................................................................................................... 37 
14.3 
Protocol Deviations ............................................................................................................... 37 
14.4 
Publication and Data Sharing Policy ..................................................................................... 38 
15 
STUDY ADMINISTRATION ........................................................................................................ 39 
15.1 
Study Leadership ................................................................................................................... 39 
16 
CONFLICT OF INTEREST POLICY ............................................................................................ 39 
17  
LITERATURE REFERENCES ...................................................................................................... 39 
APPENDIX ................................................................................................................................................. 40 
 
 
 

CLINICAL STUDY 
PROTOCOL 
 
VI0121 
Venus VivaMD 
 
Venus Concept    
CONFIDENTIAL 
Page 6 of 40 
     1.0  
January 29th, 2021 
 
SPONSOR APPROVAL/SIGNATURE PAGE 
 
Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency for the Treatment 
and Reduction of Acne Scarring 
 
The Sponsor agrees to conduct this clinical study as outlined in the approved protocol and in accordance 
with the appropriate guidelines and all applicable federal government codes, acts and regulations, the 
ethical pricinples that have their origins in the Declaration of Helsinki and all amendments, GCP 
requirements, ISO 14155:2011 (Clinical Investigation of Medical Devices for Human Subjects – Good 
Clinical Practice), Medical Devices Directive 93/42/EEC, MEDDEV 2.7/3, ICH guidance E6 on Good 
Clinical Practice, and any applicable regional or national regulations pertaining to the conduct of clinical 
investigation of a medical device. 
 
 
 
 
Sponsor Representative  
 
 
 
 
 
 
 
 
Signature ______________________________________ 
Date __________________ 
 
 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 8 of 40 
     1.0  
January 29th, 2021 
 
LIST OF ABBREVIATIONS 
 
TERM 
DEFINITION 
AE 
Adverse Event 
ASADE 
Anticipated Serious Adverse Device Effect 
CIP 
Clinical Investigation Plan 
CRF 
Case Report Form 
EC 
Ethics Committee 
FRF 
Fractional Radiofrequency 
GAIS 
Global Aesthetic Improvement Scale 
GCP 
Good Clinical Practice 
ICMJE 
International Committee of Medical Journal Editors 
ID 
Identification  
IRB 
Institutional Review Board 
ISO 14155:2011 
International Organization for Standardization Good Clinical Practices for Clinical 
Investigations of Medical Devices 
PI 
Principal Investigator 
QC 
Quality Control 
RF 
Radio Frequency 
SAE 
Serious Adverse Event 
SD 
Standard Deviation 
SE 
Standard Error 
SSS 
Subject Satisfaction Scale 
USADE 
Unanticipated Serious Adverse Device Effect 
VAS 
Visual Analog Scale 
 
STUDY SUMMARY 
 
Study Title 
Clinical Evaluation of the Safety and Performance of Fractional 
Radiofrequency for the Treatment and Reduction of Acne Scarring 
Protocol Number 
VI0121 - Protocol Version: 1.0, 29January2021 
Objectives 
The objective of this clinical study is to evaluate the safety and 
performance of FRF for the treatment and reduction of acne scarring. 
Study Design 
Non-randomized, single center, 3-treatment sessions, evaluator-blinded 
study using the Venus VivaTM MD. 
Treatment Regimen 
The study will involve up to 3 Venus VivaTM MD treatments with 4-week 
(±7 days) intervals between each treatment. Subjects will receive treatment 
according to the parameters specified in the Methods section. 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 9 of 40 
     1.0  
January 29th, 2021 
 
Return/Follow-up 
Visits 
Subjects will be followed at 6- and 12-weeks after their last treatment.   
 
Adverse Events and any changes to concomitant medications will be 
recorded. Subjects will complete a Patient Satisfaction questionnaire.  
Investigator will complete a Global Aesthetic Improvement Scale. 
Photographs of the treated area will be taken. 
Study Subjects 
Up to 20 (male and non-childbearing female) subjects requesting treatment 
of moderate to severe acne scars in Fitzpatrick skin types I-IV. Up to 10 
subjects will have skin biopsies taken for histological analyses. 
Methods 
• 
Histologic samples will be taken immediately after the first 
treatment and at final follow-up visit.  
• 
Standardized photographic images will be taken at the baseline 
visit, and at each Follow Up Visit (6- and 12-weeks post final 
treatment). 
• 
Standardized photographs will be assessed by blinded evaluators 
using the Global Aesthetic Improvement Scale (GAIS).  
Endpoints 
Primary performance endpoints  
• 
Improvement in acne scarring at 6 weeks and 12 weeks  post-
treatment compared to baseline as assessed by blinded evaluators 
by photographic assessment utilizing the Global Aesthetic 
Improvement Scale  
 
Secondary performance endpoints 
• 
Subjects’ assessment of satisfaction with the treatment using a 
Subject  Satisfaction Scale at 6 weeks and 12 weeks post-treatment. 
 
Safety endpoints 
• 
Subject’s assessment of discomfort and pain after treatments as 
measured by a 10 cm visual analog scale (VAS) and Tolerability 
Scale 
• 
Subjects experiencing a treatment-related adverse event (AE) by 12 
weeks post-treatment. 
 
Phase 
Post-Market Study 
Number of Clinical 
sites 
1 
Description of the 
Device 
The Venus Viva MD fractional RF device has been shown in clinical 
studies to improve various skin conditions related to aging and alter 
collagen structures such as wrinkles, rhytids and scars. The device offers 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 12 of 40 
     1.0  
January 29th, 2021 
 
Therefore, RF techniques that improve the ability to control the ablation and coagulation of the skin can 
result in treatment consistency that will provide more flexibility to treat a wider variety of skin conditions.  
2.2 
RATIONALE  
Fractional RF technology has been shown in clinical studies to improve skin laxity, and to treat various 
skin conditions related to aging and alternate collagen structures such as wrinkles, rhytids and scars.   
The objective of this clinical study is to evaluate the safety and performance of fractional RF for the 
treatment of  acne scarring.  
The use of the Venus Viva™ MD has been determined to present non-significant risk in accordance with 
21 CFR 812.3 for the intended use in this study, because the device is not: 
• 
Intended as an implant; 
• 
Purported or represented to be for use supporting or sustaining human life; 
• 
Substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise 
preventing impairment of human health  
• 
Otherwise presenting a potential for serious risk to the health, safety, or welfare of a subject. 
This study will be conducted in compliance with the protocol and according to Good Clinical Practice 
(GCP) standards. 
2.3 
POTENTIAL RISKS AND BENEFITS  
 
2.3.1 KNOWN POTENTIAL RISKS  
The potential risks for adverse events of the treatment procedure include but are not limited to discomfort 
or significant pain post-treatment, excessive skin redness (erythema) and/or swelling (edema), in-grown 
hairs, damage to natural skin texture (crust, blister, burn), change of pigmentation (hyper- and hypo-
pigmentation) and scarring. Treatment of hair-bearing areas in male patients may result in some damage 
to the follicles and subsequent loss of hair.  Avoid the beard area and other hair- growing zones if the 
patient does not wish to experience hair growth reduction.  
Further information about residual risks associated with the device and with participation in the clinical 
investigation are reported in the device User Manual. 
Residual risks will be mitigated as follows: 
− 
Selection of an investigator with experience in the therapeutic area of the clinical investigation 
− 
Investigator and site staff will have already undergone training prior to patients’ enrollment 
− 
Prior to the first procedure, the investigator and site staff will undergo a re-training session by the 
sponsor representative on the use of the device 
− 
Patients will be rigorously screened prior to their enrollment 
− 
Patients will be rigorously followed over the course of the study 
 
2.3.2 KNOWN POTENTIAL BENEFITS  

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 13 of 40 
     1.0  
January 29th, 2021 
 
If the subject agrees to participate in this study, he/she will be contributing to the understanding of the 
device’s impact and the biological processes that are occurring regarding acne scar formation. This 
understanding may lead to optimization of the treatment with this device for these indications.  In 
addition, the subject may benefit from improvement in acne scar appearance in the treated areas. 
3 
OBJECTIVES AND PURPOSE 
This clinical study is being conducted to evaluate the safety and performance of fractional RF for the 
treatment and reduction of acne scarring. Total expected duration of the clinical investigation is eight 
months (enrolment period of 2 months, follow-up period of 6 months), while individual subject 
participation will take approximately 6 months. 
4 
STUDY DESIGN AND ENDPOINTS 
 
4.1 
DESCRIPTION OF THE STUDY DESIGN 
This is a prospective, evaluator-blind study of the safety and performance of fractional RF for the 
treatment and reduction of acne scarring. 
4.2.1 PRIMARY ENDPOINT 
• 
Improvement in acne scarring at 6 weeks and 12 weeks  post-intervention compared to baseline 
as assessed by blinded evaluators by photographic assessment utilizing the Global Aesthetic 
Improvement Scale (GAIS) for acne scarring. 
4.2.2 SECONDARY ENDPOINTS 
• 
Subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale  at 6 
weeks and 12 weeks post-treatment. 
4.2.3 EXPLORATORY ENDPOINTS 
• 
Subjects’ assessment of discomfort and pain after treatments as measured by a 10 cm visual 
analog scale (VAS). 
• 
Subjects experiencing a treatment-related adverse event (AE) by 12 weeks post-treatment. 
5 
STUDY ENROLLMENT AND WITHDRAWAL 
 
5.1 
PARTICIPANT INCLUSION CRITERIA 
1. Healthy, male or female subjects over 21 years of age who are seeking treatment and reduction of 
their acne scarring. 
2. Able to read, understand and voluntarily provide written Informed Consent. 
3. Able and willing to comply with the treatment/follow-up schedule and requirements. 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 14 of 40 
     1.0  
January 29th, 2021 
 
4. Women of child-bearing age are required to be using a reliable method of birth control at least 3 
months prior to study enrollment and for the duration of the study and have a negative Urine 
Pregnancy test at baseline. 
5.2 
PARTICIPANT EXCLUSION CRITERIA 
1. Implantable defibrillators, cardiac pacemakers, and other metal implants 
2. Subjects with any implantable metal device in the treatment area 
3. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body 
(e.g. cochlear implant). 
4. Permanent implant in the treated area, such as metal plates and screws, or an injected chemical 
substance. 
5. Current or history of any kind of cancer, or pre-malignant moles. 
6. Severe concurrent conditions, such as cardiac disorders. 
7. Pregnancy or intending to become pregnant during the study and nursing. 
8. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of 
immunosuppressive medications. 
9. History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; 
may be enrolled only after a prophylactic regime has been followed for 2 weeks or longer prior to 
enrollment, or according to Investigator’s discretion. 
10. Poorly controlled endocrine disorders, such as diabetes. 
11. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. 
12. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and 
fragile skin. 
13. History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin). 
14. Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if 
face is treated. 
15. Use of isotretinoin (Accutane®) or other systemic retinoids within six months or topical retinoids 
within three months prior to treatment; or as per physician’s discretion. 
16. Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen-containing agents) one 
week before and after each treatment session. 
17. Any surgical procedure in the treatment area within the last six months or before complete 
healing. 
18. Treating over tattoo or permanent makeup. 
19. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks. 
20. As per the practitioner's discretion, refrain from treating any condition which might make it 
unsafe for the patient. 
5.3 
STRATEGIES FOR RECRUITMENT AND RETENTION 
Male or female subjects requesting treatment for the reduction of acne scarring will be enrolled at the 
single investigative site until a total of 20 patients have been treated according to the study protocol.  It is 
anticipated that it will take up to eight months to complete the study.  Subjects will  primarily be recruited 
from the investigator’s practice.  Any advertising campaigns and materials will be reviewed and approved 
by an Ethics Committee or Institutional Review Board (EC or IRB) before implementation. Due to the 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 15 of 40 
     1.0  
January 29th, 2021 
 
long duration of the study, subjects will be contacted by the investigative site on a regular basis to 
enhance retention. 
5.4 
PARTICIPANT WITHDRAWAL OR TERMINATION 
 
5.4.1 REASONS FOR WITHDRAWAL OR TERMINATION 
Subjects are free to withdraw from participation in the study without prejudice at any time upon request.  
In the event that a subject drops out of the study or is withdrawn from the study, the End of Study/Early 
Discontinuation CRF form should be completed.  On the discontinuation page, the Investigator should 
record the date of the withdrawal and the reason for withdrawal.  
Reasonable effort should be made to contact any subject lost to follow up during the course of the study 
in order to complete assessments and retrieve any outstanding data.  The records of subjects who 
terminate prior to completing the study will be retained and the reason for termination will be 
documented. 
The investigator may terminate participation in the study if: 
• 
Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
subject. 
• 
The subject meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation. 
5.4.2 HANDLING OF PARTICIPANT WITHDRAWALS OR TERMINATION 
Every effort will be made to continue follow-up of withdrawn or terminated subjects or subjects who 
discontinue the intervention but remain in the study for follow-up, especially for safety and performance 
study endpoints.  Every effort will be made to conduct an exit visit (final study visit, see section 7.3.5) to 
withdrawn patients, and to undertake protocol-specified safety follow-up procedures to capture AEs, 
serious adverse events (SAEs) and device deficiencies.  
5.5 
PREMATURE TERMINATION OR SUSPENSION OF STUDY 
The sponsor may suspend or prematurely terminate this study at the investigation site for significant and 
documented reasons. 
 
A principal investigator, EC/IRB, or regulatory authority may suspend or prematurely terminate 
participation in the study at the investigation site for which they are responsible. 
 
If suspicion of an unacceptable risk to subjects arises during the study, or when so instructed by the EC/IRB 
or regulatory authorities, the sponsor shall suspend the clinical investigation while the risk is assessed.  The 
sponsor shall terminate the study if an unacceptable risk is confirmed. 
 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 16 of 40 
     1.0  
January 29th, 2021 
 
The sponsor shall consider terminating or suspending the participation of the investigation site or 
investigator in the study if monitoring or auditing identifies serious or repeated deviations on the part of an 
investigator. 
 
If suspension or premature termination occurs, the terminating party shall justify its decision in writing and 
promptly inform the other parties with whom they are in direct communication. The principal investigator 
and sponsor shall keep each other informed of any communication received from either the EC/IRB or the 
regulatory authority. 
 
If, for any reason, the sponsor suspends or prematurely terminates the study at the investigation site, the 
sponsor shall inform the responsible regulatory authority as appropriate and ensure that the EC/IRB is 
notified, either by the principal investigator or by the sponsor.  If the suspension or premature termination 
was in the interest of safety, the sponsor shall inform all other principal investigators. 
 
If suspension or premature termination occurs, 
a) the sponsor shall remain responsible for providing resources to fulfil the obligations from the 
clinical investigative plan and existing agreements for following up the subjects enrolled in the 
study, and 
b) the principal investigator or authorized designee shall promptly inform the enrolled subjects at the 
investigation site, if appropriate 
 
In case of early termination, final study activities according to the protocol, including the follow up visits 
and procedures to assess the safety and efficacy of the device will be conducted, regardless of the sponsor's 
interest in the study.  Follow-up activities will be conducted so that device deficiencies can be identified 
and appropriate safety measures can be implemented. 
 
At the completion or termination of the study, the Investigator will return all remaining clinical supplies to 
Sponsor along with a copy of the device supply and inventory records. 
 
Circumstances that may warrant termination or suspension include, but are not limited to: 
• 
Determination of unexpected, significant, or unacceptable risk to participants (examples of 
findings that might trigger a safety review are the number of SAEs overall, the number of 
occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of events – 
refer to section 8.5 STUDY HALTING RULES. 
• 
Demonstration of performance that would warrant stopping 
• 
Insufficient compliance to protocol requirements 
• 
Data that are not sufficiently complete and/or evaluable 
• 
Determination of futility 
Study may resume once concerns about safety, protocol compliance, data quality are addressed and 
satisfy the sponsor, EC / IRB and/or regulatory authorities. 
6 
INVESTIGATIONAL DEVICE 
 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 17 of 40 
     1.0  
January 29th, 2021 
 
6.1 
INVESTIGATIONAL DEVICE AND CONTROL DESCRIPTION 
 
6.1.1 ACQUISITION  
If the investigative site does not own a Venus Viva™ MD, a device will be provided by the sponsor.  An 
activation code will be required to activate the device (not applicable if the site owns the device).  This 
code will be provided to the investigative site once all regulatory and EC/IRB approvals are in place and 
the site has received training for both the device and the study (if applicable).  
6.1.2 DEVICE SPECIFIC CONSIDERATIONS 
• 
Device model(s) - Venus Viva™ MD 
• 
Device settings and programming – Ablation and Coagulation Mode; 180-280 volts, 5-30 ms 
pulse duration 
• 
Duration of exposure and frequency –   
o For all subjects - monthly treatment for 3 months.   
The Venus Viva™ MD is a non-invasive medical aesthetic device, intended for use in dermatologic and 
general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.   
The system consists of a handheld applicator with disposable tips. The tip options include an 80 pin  tips, 
8x20 mm in size, that delivers the Multi Polar Radiofrequency (RF) to the skin.  Further details about the 
Venus Viva™ MD can be found in the device User Manual. 
6.2 
INVESTIGATIONAL DEVICE ACCOUNTABILITY PROCEDURES 
If the device is supplied by the sponsor, traceability shall be achieved during and after the clinical 
investigation by assignment of serial numbers to device and applicators.  Disposal tips will be provided 
by the sponsor. 
7.1 
STUDY PROCEDURES/EVALUATIONS 
7.1.1 STUDY SPECIFIC PROCEDURES  
The following procedures and evaluations will be done as part of the study: 
Demographics 
Medical /surgical history (obtained by interview and/or medical records) 
Physical examination 
Assessment of eligibility 
Photographs  
Blinded assessment  
Administration of questionnaires and scales for blinded reviewer and patient-reported outcomes 
Adverse event recording 
Concomitant medications 
7.2 
LABORATORY PROCEDURES/EVALUATIONS 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 18 of 40 
     1.0  
January 29th, 2021 
 
 
7.2.1 CLINICAL LABORATORY EVALUATIONS  
Urine pregnancy test to be performed within 24 hours of study intervention with results available prior to 
administration of treatment.    
 
For up to 10 subjects, histological samples of a separate treated area will be obtained at baseline, 
immediate/post procedure, 2 weeks and at the final 3 month visit. 
7.3 
STUDY SCHEDULE 
 
7.3.2 ENROLLMENT/BASELINE/SCREENING 
 
Screening Visit and Enrolment (Day -7 to -2) 
If the subject meets the preliminary study criteria, the study doctor, and/or his/her designee, will obtain an 
informed consent from the subject prior to any study procedure, clearly indicating his/her understanding 
of the requirements and possible risks associated with study participation and other applicable treatment 
options.  Subjects will receive a unique identifying number that will be composed of a two-digit site 
number and a two-digit subject number in sequence.  This unique identifier will be used throughout the 
entire study and will be entered in the subject's case report form (CRF).  
During the first visit, the study investigator, and/or his/her designee, will screen the subject for eligibility 
to participate in the clinical study using the inclusion/exclusion criteria.  A negative urine pregnancy test 
will be obtained (in patients of child-bearing potential).  During screening, the study doctor will review 
the subject's medical/surgical history, demographics, physical exam and examine the subject's targeted 
treatment area to ensure that it meets the study criteria.  The subject will complete screening and the 
treatment will be scheduled.  
Test Spots 
A small test spot will be performed in a non-conspicuous area of the treatment site, prior to the first 
complete session. Test spots are performed to establish the following requirements: 
• 
Confirm the patient's suitability for treatment:  
o For skin types I-III, wait 24-48 hours  
o For skin type IV-VI, wait 5 – 7 days before assessing the skin response 
• 
Establish and confirm treatment parameters:  If the desired endpoint of erythema and edema – in 
a tip-shaped pattern – has not been achieved within 10-15 minutes, increase the RF indicator level 
and perform another test spot.  If the response is excessive, decrease the parameters and perform 
another test spot. 
Test spot results will indicate if the patient can tolerate the treatment without developing adverse effects.  
According to patient tolerance to the test spot, treatment parameters are determined and whether 
anesthesia is needed.  In addition, it is advisable to perform a test spot whenever changing parameters.  
7.3.2 BASELINE VISIT 
Baseline Visit (Visit 1 – Day 0) 
Subjects will return to the clinic within 2-7 days from the Screening visit for the Baseline visit and the 
first of three treatments (see 7.3.3).  The subject’s eligibility status at this timepoint according to the 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 19 of 40 
     1.0  
January 29th, 2021 
 
inclusion/exclusion criteria will be re-confirmed.  Test spot assessment, photographs, AEs and any 
changes to concomitant medications will be recorded. For patients who volunteer to receive a biopsy for 
histological assessment, a punch biopsy of an untreated area will be obtained. This separate assessment 
area for the biopsy may be designated to a non-conspicuous area such as behind the ear. 
7.3.3 TREATMENT VISITS  
Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 
weeks apart.  The left and right side of the face will be treated and assessed as independent sites, and the 
same applicator tip configuration will be used to treat both sides at all 3 treatment visits.  Adverse events 
and any changes to concomitant medications will be recorded at these visits. 
Subjects will receive treatment as described below.  Following treatment, the investigator will examine 
the treated area and report immediate and short term response.  Subjects will complete the 10 cm 
discomfort/pain VAS and Tolerability Scale immediately after treatment.   
The investigator will examine the treated areas and report immediate and short term response (30 minutes 
post-treatment) (pain during treatment, hemorrhage, burn, erythema, edema, purpura) using a 5-point 
scale: 1=none; 2=trace; 3=moderate; 4=marked; 5=severe.   
The normal response to these treatments is transient erythema and edema. If any other side effects occur, 
as indicated in the protocol, they must be recorded. 
Visit 1 – Day 0 
This Baseline visit includes the first of the three treatments. Photographs of the treatment area are to be 
taken prior to treatment.  Based on the test spot evaluation from the previous visit, treatment parameters 
will be selected by the investigator.  In addition to the treatment, concomitant medications, AEs and the 
pain VAS and Tolerability Scale are to be completed by the patient. For patients who volunteer to receive 
a biopsy for histological assessment, a punch biopsy of the separate treated area will be obtained prior to 
and immediately post-treatment.   
Histology Visit – Week 1 (+/- 7 days) 
Patients who volunteer to the Histological assessment subgroup are to return to the clinic for the Week 1 
biopsy. A punch biopsy of the separate treated area will be obtained at this visit. In addition to the biopsy, 
any AEs or changes to concomitant medications will be recorded. 
Visit 2 – Week 4 (+/- 7 days) 
The Subject is to return to the clinic for their second of the three treatments.  In addition to the treatment, 
concomitant medications,  AEs and the pain VAS and Tolerability Scale are to be completed by the 
patient. 
Visit 3 -- Week 8 (+/- 7 days) 
The Subject is to return to the clinic for their final treatment.  In addition to the treatment, concomitant 
medications,  AEs and the pain VAS and Tolerability Scale are to be completed by the patient. 
Treatment 
Subjects will be asked to present to the clinic clean shaven prior to receiving treatment.  There should be 
no lotion, make-up, perfume, powder, or bath/shower oil present on the skin in the area to be treated. 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 20 of 40 
     1.0  
January 29th, 2021 
 
Ensure that the skin is completely dry during the entire treatment. If the skin moistens during treatment 
(i.e. perspiration, etc.) re-wipe the skin with an alcohol pad and ensure that the skin is completely dry 
before continuing the treatment. 
Depending upon the subject’s sensitivity to the test spot administration, a topical anesthetic may be 
prescribed and applied to the treatment area prior to treatment at the investigator’s discretion.  This 
topical anesthetic should be applied approximately one hour to thirty minutes prior to study treatment. 
Set the treatment parameters to desired treatment mode. The selected 80 pin tip will be utilized for all of 
the specific patient’s subsequent treatments. Set the desired energy level according to the skin type, 
severity of the treated condition, treatment area, bone proximity, etc. Set conservative parameters from a 
test spot for the first treatment, and then gradually increase during treatment or in subsequent treatments 
according to the desired impact and test spot results. 
To perform the treatment, place the tip on the target zone, perpendicular to the skin surface and with full 
contact with the skin.  Emit a pulse by pressing the applicator's trigger; this will create a tip-shaped 
pattern on the patient's skin that will appear 1-2 minutes later. Move the applicator to an adjacent spot on 
the skin overlapping by 10% and emit another pulse (not applicable to the test spot). There should be no 
untreated gaps between the pulses.  
Examine the treated area. The immediate responses, indicative of the desired effect, are erythema and 
edema in the immediate area of the tip-shaped pattern and possibly also around it. The edema usually 
appears 1-2 minutes after pulsing and reaches its peak (of up to moderate edema) within 30 minutes. It 
should be noted that erythema is not easily noticeable – if at all – in darker skin types. Therefore, the 
edema will be more prominent in these patients. After completing a full pass on the entire treatment area, 
if untreated patches of skin are apparent, re-treat these patches as per the following procedure: 
i. Wipe the untreated patch of skin with a dry gauze pad. 
ii. Treat the untreated patches of skin as normally. 
Fine-tuning of the parameters should be done before proceeding to treatment of the entire sub-area with 
the selected parameters. The applicator tip should be placed on the skin, a pulse emitted, then lifted and 
moved to an adjacent spot of the skin. The emitted pulses should create tip-shaped patterns. Leave, no 
untreated gaps between the pattern marks, while also being careful not to overlap the treated zones. The 
parameters can be modified during subsequent visits, as per the practitioner's discretion. 
Post-Treatment Care 
Post-treatment cooling is not necessary.  In the event of post-treatment discomfort, it is recommended to 
cool the treated area immediately with air cooling.  Cold (not frozen) packs may also be used. Blistered or 
ulcerated skin can be treated with a prescribed cream. Tiny scabs of less than 1 mm diameter will usually 
form 24-72 hours post-treatment and may remain for several days. The scabs should not be touched or 
scratched even if they itch, and should be allowed to shed off naturally. Blistered or ulcerated skin can be 
treated with a prescribed antibiotic ointment or burn treatment cream as per physician's discretion.  
During the first two days following treatment, care should be taken to prevent trauma to the treated site.  
Hot baths, massage, etc. should be avoided. The skin should be kept clean to avoid contamination or 
infection.  Any mechanical or thermal damage to the area must be avoided.  Moisturizer may be applied 
only 24 hours after each treatment, and then should be applied regularly throughout the course of the 
treatment.  Make-up may be applied only 24 hours after each treatment if desired, unless an unwanted 
reaction occurs in the area.  Generally, 24 hours after treatment, patients may use regular soaps, but not 
scrub soaps or exfoliants. The patient should use a high-factor sunscreen (at least 30 SPF) and protect the 
treated area from sunlight for at least one month after the treatment.  Tanning of any sort (sun exposure, 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 21 of 40 
     1.0  
January 29th, 2021 
 
tanning beds, and artificial sunless tanning lotions) is not allowed in the treated areas during the entire 
course of the treatment.  Tanning after treatment may cause hyperpigmentation.  
Photography 
Photographs will be taken prior to first treatment and throughout the study according to specified time 
points detailed in the Schedule of Events Table (section 7.3.7), utilizing standard scientific equipment.     
The photos should be taken in a private room or area of the clinic under controlled conditions, including 
the distance, angle, background and lighting in order to achieve high-quality sets of photographs.   The 
subject should be placed in the same position each time.  As each photograph is taken, it should be 
viewed to ensure that it is in focus and is similar to its baseline counterpart in all technical aspects, 
including lighting, distance and angle. 
For consistency purposes, the same person should ideally take all study photographs, especially per 
subject.  The digital files should follow a consistent standard naming scheme. 
7.3.3 FOLLOW-UP  
Visit 4 – 6 Week Follow Up Post Final Treatment (+/- 7 days) 
Subjects will return to the clinic 6 weeks after the final treatment.  Adverse events, and any changes to 
concomitant medications will be recorded.  Subjects will complete a Subject Satisfaction Scale and 
Treatment Evaluation Questionnaire. 
Photographs of the treated area will be taken as described in section 7.3.3. The photographs will be sent to 
the blinded independent reviewer for the Global Aesthetic Improvement Scale (GAIS) assessment.   
Visit 5 – 12 Week Follow Up Post Final Treatment (+/- 7 days) 
Subjects will return to the clinic for a final study visit 12 weeks after the final treatment.  Adverse events, 
and any changes to concomitant medications will be recorded.  Subjects will complete a Subject  
Satisfaction Scale and Treatment Evaluation Questionnaire. 
Photographs of the treated area will be taken as described in section 7.3.3. The photographs will be sent to 
the blinded independent reviewer for GAIS assessment.   
The termination form will be completed, and subjects will be terminated from the study.  The PI will 
record all reportable events with start dates occurring any time after informed consent is obtained until 7 
(for non-serious AEs) or 30 days (for SAEs) after the last day of study participation. 
7.3.5 EARLY TERMINATION VISIT 
If a subject requests to exit the study early for any reason, a Termination CRF must be completed.  
Adverse events and the reason for early termination will be recorded. 
7.3.7 SCHEDULE OF EVENTS TABLE 
 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 23 of 40 
     1.0  
January 29th, 2021 
 
Use of immunosuppressive medications, anticoagulants, isotretinoin and non-steroidal anti-inflammatory 
drugs is prohibited.   
7.7 
PROPHYLACTIC MEDICATIONS, TREATMENTS, AND PROCEDURES  
Prophylactic regime for history of diseases stimulated by heat, such as recurrent herpes simplex in the 
treatment area. 
7.8 
RESCUE MEDICATIONS, TREATMENTS, AND PROCEDURES  
In the event that the subject experiences pain, the principal investigator may prescribe any analgesic 
deemed appropriate to the level of pain. If a subject experiences any first, second or third degree burn or 
pain beyond narcotics, then the following procedure will be implemented: 
• 
Immediate triage and treatment of the patient shall be determined by the treating physician and 
based upon severity and type of burn identified.  
• 
The event will be reported to the sponsor study Director within 24 hours of occurrence. If the 
event meets the criteria of a SAE, then it must be reported on the SAE form. 
• 
An anonymized copy of the patient chart and treatment parameters are to be forwarded to the 
sponsor study Director within 24 hours.   
The sponsor study Director will be responsible for issuing a written report to the company and the EC or 
IRB Chairman no later than 7 days from the event   
Long term follow up and care shall continue at the discretion of the treating physician.  
All patients experiencing a complication of the device will be followed a minimum of 2 years following 
the initial injury.  Longer care and observation will be at the discretion of the treating physician.   
All minor complications such as appearance or altered sensation, except for pain, can be reported within 
30 days of patient complaint.  Both chart and treatment parameters are to be provided to the study 
Director and shared with the company and EC or IRB chairman.  
8 
ASSESSMENT OF SAFETY 
 
8.1 
SPECIFICATION OF SAFETY PARAMETERS 
In addition to spontaneous reports of adverse events, subjects will complete a 10 cm discomfort/pain 
VAS, Tolerability Scale and the principal investigator will examine the treated area and report immediate 
and short term response. 
8.1.1 DEFINITION OF ADVERSE EVENTS (AE) 
Adverse event means any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the investigational medical device. This definition includes events related to the investigational 
medical device or the comparator. This definition includes events related to the procedures involved.  For 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 24 of 40 
     1.0  
January 29th, 2021 
 
users or other persons, this definition is restricted to events related to investigational medical devices (ISO 
14155:2011). 
Adverse device effect means any adverse event related to the use of an investigational medical device. 
This definition includes adverse events resulting from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical 
device. This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device (ISO 14155:2011). 
8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE) 
NOTE: The term serious is not synonymous with severity, which may be used to describe the intensity of 
an event experienced by the subject).  An AE that does not meet any of the below criteria will be 
classified as non-serious. 
A serious AE is any adverse event that: 
• 
led to death, 
• 
led to serious deterioration in the health of the subject, that either resulted in 
− 
a life-threatening illness or injury, or 
− 
a permanent impairment of a body structure or a body function, or 
− 
in-patient or prolonged hospitalization, or 
− 
medical or surgical intervention to prevent life-threatening illness or injury or permanent 
impairment to a body structure or a body function, 
• 
led to fetal distress, fetal death or a congenital abnormality or birth defect 
Planned hospitalization for a pre-existing condition, or a procedure required by the CIP, without serious 
deterioration in health, is not considered a serious adverse event (ISO 14155:2011). 
8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS (UP) 
This definition includes any adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event.  Unanticipated serious adverse device effect (USADE) is any 
serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in 
the current version of the risk analysis report.  Anticipated serious adverse device effect (ASADE) is an 
effect which by its nature, incidence, severity or outcome has been identified in the risk analysis report 
(ISO14155:2011). 
8.1.4 DEFINITION OF DEVICE DEFICIENCY 
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or 
performance. Device deficiencies include malfunctions, use errors, and inadequate labelling (ISO 
14155:2011). 
Any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action had not 
been taken or b) intervention had not been made or c) if circumstances had been less fortunate is subject 
to the same reporting requirement of SAEs (MEDDEV 2.7/3 revision 3). 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 25 of 40 
     1.0  
January 29th, 2021 
 
8.2 
CLASSIFICATION OF AN ADVERSE EVENT 
 
8.2.1 SEVERITY OF EVENT 
For AEs not included in the protocol defined grading system, the following guidelines will be used to 
describe severity. 
• 
Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities. 
• 
Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures.  Moderate events may cause some interference with functioning. 
• 
Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life-threatening or incapacitating. 
8.2.2 RELATIONSHIP TO STUDY AGENT 
The clinician’s assessment of an AE's relationship to the investigational device is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the study.  If there 
is any doubt as to whether a clinical observation is an AE, the event should be reported.  All AEs must 
have their relationship to investigational device assessed.  In a clinical trial, the study product must 
always be suspect. To help assessment, the following guidelines are used. 
• 
Not Related – relation to the device or procedure can be excluded when: 
− The event is not a known side effect of the product category the device belongs to or of similar 
devices and procedures; 
− the event has no temporal relationship with the use of the investigational device or the procedures; 
− the serious event does not follow a known response pattern to the medical device (if the response 
pattern is previously known) and is biologically implausible 
− the discontinuation of medical device application or the reduction of the level of 
activation/exposure - when clinically feasible – and reintroduction of its use (or increase of the 
level of activation/exposure), do not impact on the serious event; 
− the event involves a body-site or an organ not expected to be affected by the device or procedure; 
− the serious event can be attributed to another cause (e.g. an underlying or concurrent illness/ 
clinical condition, an effect of another device, drug, treatment or other risk factors). 
• 
Unlikely: the relationship with the use of the device seems not relevant and/or the event can be 
reasonably explained by another cause, but additional information may be obtained. 
• 
Possible: the relationship with the use of the investigational device is weak but cannot be ruled out 
completely.  Alternative causes are also possible (e.g. an underlying or concurrent illness/ clinical 
condition or/and an effect of another device, drug or treatment).  Cases were relatedness cannot be 
assessed or no information has been obtained should also be classified as possible. 
• 
Probable: the relationship with the use of the investigational device seems relevant and/or the event 
cannot reasonably be explained by another cause, but additional information may be obtained. 
• 
Causal relationship: the serious event is associated with the investigational device or with 
procedures beyond reasonable doubt when: 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 26 of 40 
     1.0  
January 29th, 2021 
 
− 
the event is a known side effect of the product category the device belongs to or of similar 
devices and procedures; 
− 
the event has a temporal relationship with investigational device use/application or procedures; 
− 
the event involves a body-site or organ that the investigational device or procedures are applied to 
or the investigational device or procedures have an effect on; 
− 
the serious event follows a known response pattern to the medical device (if the response pattern 
is previously known); 
− 
the discontinuation of medical device application (or reduction of the level of 
activation/exposure) and reintroduction of its use (or increase of the level of activation/exposure), 
impact on the serious event (when clinically feasible); 
− 
 other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and an effect 
of another device, drug or treatment) have been adequately ruled out; 
− 
harm to the subject is due to error in use.  
8.2.3 EXPECTEDNESS  
Expected (anticipated) adverse reactions are AEs that are common and known to occur for the 
investigational device being studied.  Expected adverse events in this study include discomfort or 
significant pain post-treatment, excessive skin redness (erythema) and/or swelling (edema), in-grown 
hairs, damage to natural skin texture (crust, blister, burn), change of pigmentation (hyper- and hypo-
pigmentation), scarring. Treatment of hair-bearing areas in males may result in some damage to the 
follicles and subsequent loss of hair.  
An AE or suspected adverse reaction is considered "unexpected" (unanticipated) if it is not known to 
occur for the investigational device being studied and at the specificity or severity that has been observed 
(AE not described into the Clinical protocol or User Manual). 
8.3 
TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-
UP 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs 
including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate CRF. Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to investigational device and study procedures (assessed only by 
those with the training and authority to make a diagnosis), and time of resolution/stabilization of the 
event. All AEs occurring while on study must be documented appropriately regardless of relationship. All 
AEs will be followed to adequate resolution. 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time 
during the study, it will be recorded as an AE. 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 27 of 40 
     1.0  
January 29th, 2021 
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of 
onset and duration of each episode. 
The PI will record all adverse events with start dates occurring any time after informed consent is 
obtained. At each study visit, the investigator will inquire study subjects about the occurrence of 
AE/SAEs since the last visit. All adverse events need to be followed until resolution or until study end, 
whichever occurs first. 
8.4 
REPORTING PROCEDURES 
 
8.4.1 ADVERSE EVENT REPORTING  
All AEs will be recorded on the appropriate CRF and will include information about the start and stop 
dates, severity and relatedness. There should be an attempt to report a “diagnosis” rather than the 
individual signs, symptoms and abnormal laboratory values associated with the diagnosis. However, a 
diagnosis should be reported only if, in the Investigator’s judgment, it is relatively certain (i.e., definite or 
possible). Otherwise individual signs, symptoms and abnormal laboratory values should be reported as 
distinct adverse events. 
8.4.2 SERIOUS ADVERSE EVENT REPORTING  
All serious AE, whether or not deemed procedure or device related, must be reported to the sponsor’s 
clinical research department immediately or within 24 hours by telephone or by email (see contact details 
below). 
 
  
 
A written report prepared by the Principal Investigator (or designate) must follow within seven working 
days to the clinical monitor and should include a full description of the event and sequence. 
The study investigator shall complete a Serious Adverse Event / Serious Adverse Device Effect Form and 
submit to the study sponsor as soon as possible, but in no event later than 10 working days after the 
investigator first learns of the effect. 
In accordance with the requirements of Directive 93/42/EEC, and with MEDDEV 2.7/3, the following 
events are considered reportable events: 
1. any SAE (whether or not study procedure or device related), 
2. any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action 
had not been taken or b) intervention had not been made or c) if circumstances had been less 
fortunate, 
3. new findings/updates in relation to already reported events. 
 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 28 of 40 
     1.0  
January 29th, 2021 
 
The sponsor will report the above-mentioned events to the Competent Authorities of all countries where 
the study is being conducted, within the following timelines: 
− 
Any SAE which indicates an imminent risk of death, serious injury, or serious illness AND that 
requires prompt remedial action for other patients/subjects, users or other persons or a new 
finding to it: immediately, but not later than 2 calendar days after awareness by sponsor of a new 
reportable event or of new information in relation with an already reported event. 
− 
Any other reportable event or a new finding / update to it: immediately, but not later than 7 
calendar days following the date of awareness by the sponsor of the new reportable event or of 
new information in relation with an already reported event. 
 
Reporting of the events listed above (under bullets 1-3) to the ECs of the participating sites and to the 
other investigators will be performed according to country and/or site-specific requirements. 
 
8.4.5 REPORTING OF PREGNANCY  
If a subject becomes pregnant during the course of the study, the subject will be terminated from the 
study. The pregnancy will be immediately reported to the sponsor on the Notification of Subject or 
Partner Pregnancy form using the same reporting timelines as a SAE. The investigator will follow the 
pregnancy until completion and will report the outcome of the pregnancy to the sponsor on the 
Notification of Subject or Partner Pregnancy Outcome form within 10 business days. 
8.5 
STUDY HALTING RULES  
The study may be halted at any time by the sponsor, the EC / IRB, Competent Authorities due to safety 
concerns. Examples of findings that might trigger a safety review are the number of SAEs overall, the 
number of occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of 
events. If the study is halted, the sponsor will immediately notify all investigational sites, the EC / IRB(s), 
the Competent Authorities of all countries where the study is being conducted. 
8.6 
SAFETY OVERSIGHT 
Independent oversight is an important component to ensure human subjects' protection. Safety oversight 
will be under the direction of the sponsor and a medical monitor. 
9 
CLINICAL MONITORING 
Clinical site monitoring is conducted to ensure that the rights and well-being of human subjects are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of the 
trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable 
regulatory requirement(s). 
• 
Monitoring for this study will be performed by the sponsor or designate. 
• 
Regular monitoring and an independent audit, if conducted, will be performed according to ISO 
14155:2011. 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 29 of 40 
     1.0  
January 29th, 2021 
 
10 
STATISTICAL CONSIDERATIONS  
 
10.1 
STATISTICAL AND ANALYTICAL PLANS 
The Statistical and Analytical Plan (SAP) may be revised during the study to accommodate Clinical Trial 
Protocol Amendments and to make changes to adapt to unexpected issues in study execution and data that 
affect planned analyses. If revised, a formal SAP will be completed and issued prior to database lock and 
unblinding of the study data, if applicable.    
10.2 
STATISTICAL HYPOTHESES 
The null and alternative hypotheses for the study’s primary, key secondary and safety endpoints are;  
• 
Primary Performance Endpoint: 
o Null Hypothesis (Ho: μd = μpost – μpre = 0) – There is no change (improvement) in 
GAIS mean score from baseline to 6 and 12 weeks post-treatment. 
o Alternative Hypothesis (Ha: μd = μpost – μpre ≠ 0) – There is change (improvement) 
in GAIS mean score from baseline to 6 and 12 weeks post-treatment. The improvement 
of striae will be defined by GAIS evaluated by independent blinded evaluators.  
 
• 
Secondary Performance Endpoint(s): 
o Null Hypothesis (Ho: μd = μpost – μpre = 0) – There is no change (improvement) in 
SSS mean score from baseline to 6 and 12 weeks post-treatment.  
Alternative Hypothesis (Ha: μd = μpost – μpre ≠ 0) – There is change (improvement) 
in SSS mean score from baseline to 6 and 12 weeks post-treatment. The improvement of 
striae will be evaluated by the subjects using the 5-point SSS.  
 
• 
Safety Endpoint: 
o Null Hypothesis (Ho: μd = μpost – μpre = 0) – There is no difference in subjects’ 10 
cm discomfort/pain VAS score. 
Alternative Hypothesis (Ha: μd = μpost – μpre ≠ 0) – There is a difference in 
subjects’ 10 cm discomfort/pain VAS score. 
 
o Null Hypothesis (Ho: μd = μpost – μpre = 0) – There is no difference in subjects’ 
tolerability score. 
Alternative Hypothesis (Ha: μd = μpost – μpre ≠ 0) – There is a difference in 
subjects’ tolerability score. 
 
10.3 
ANALYSIS DATASETS 
Modified Intention-to-Treat Analysis Dataset will be used; Efficacy and safety analyses will be carried out 
on all subjects who received at least one treatment of Venus Viva™ MD fractional RF device and for whom 
at least one valid post-baseline efficacy and safety evaluation were obtained.  

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 30 of 40 
     1.0  
January 29th, 2021 
 
10.4 
DESCRIPTION OF STATISTICAL METHODS 
 
10.4.1 GENERAL APPROACH 
This is a prospective, single center, evaluator-blind study of the safety and performance of fractional 
radiofrequency (RF) for the treatment and reduction of facial acne scarring.   
All summary tables for quantitative parameters will display mean, standard deviation, median, range 
(minimum and maximum), percentages as well as number of missing data (if relevant). All summary tables 
for qualitative parameters will display counts, percentages and number of missing data if relevant. Baseline 
data are defined as the last measurement, photograph or assessment performed before the first treatment on 
Visit 2.  
All statistical tests will be one-sided. The level of statistical significance for effectiveness analyses is 5% 
(α = 0.05) for all tests of differences. Where appropriate, Paired t-test and/or Wilcoxon Signed-Ranks Test 
for Matched Pairs will be used to compare the evaluations at the baseline and post treatment sessions. This 
test will enable us to accept or reject the null hypotheses. Rejection of null hypotheses will establish that: 
• 
The one-sided 95% confidence interval for the difference between the means excludes zero. 
• 
The two means are statistically significantly different at the 5% level (P < 0.05) one-sided. 
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t-test will 
be used to determine the efficacy of the treatment. 
In other to accommodate imbalances of some baseline GAIS scores, covariate adjustment analysis may be 
performed in SAP to estimate adjusted treatment effects for the primary endpoint analysis. 
The assumption for the statistical test is that the paired differences of baseline and post treatment data are 
normally distributed.  
10.4.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S) 
The following will be considered for the analysis primary endpoint: 
Summary table for differences of baseline compared to 6-week and baseline compared to 12-week post-
treatment GAIS scores will be displayed as mean difference, standard deviation and standard error.  The 
Global Aesthetic Improvement Scale (GAIS) is a 6-level ordinal scale tool for assessing reduction of acne 
scarring. 
 
Bar, pie charts or graphs indicating scores, percentages or proportions of subjects with Global Aesthetic 
Improvement Scale (GAIS). 
 
All statistical tests will be one-sided. The level of statistical significance for effectiveness analyses is 5% 
(α = 0.05) for all tests of differences. Where appropriate, Paired t-test and/or Wilcoxon Signed-Ranks Test 
for Matched Pairs will be used to compare the evaluations between baseline and 6-week as well as baseline 
and 12-week post treatment assessments. Analysis of Covariance (ANCOVA) may also be used where 
appropriate. Since the primary endpoint is based on achieving a fixed scale point on the GAIS, covariate 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 31 of 40 
     1.0  
January 29th, 2021 
 
adjustment analysis may be performed in SAP to estimate adjusted treatment effects for the primary 
endpoint analysis in covariate adjustment analysis may be performed in SAP to estimate adjusted treatment 
effects for the primary endpoint analysis.  
The Paired t-test and/or Wilcoxon Signed-Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that: 
• 
The one-sided 95% confidence interval for the difference between the means excludes zero. 
• 
The two means are statistically significantly different at the 5% level (P < 0.05) one-sided. 
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t-test will 
be used to test expected primary endpoint; that is alternative hypothesis that Ha > 1. This will be used to 
determine if the study meets the primary endpoint; GAIS score of > 0.75. 
GAIS scores of all subjects who received at least one treatment of Venus Viva™ MD fractional RF 
device and for whom at least one valid post-baseline GAIS assessment were obtained will be analyzed for 
the primary endpoint. Multiple imputation method or modelling of available data may be used for missing 
data as appropriate. 
10.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S) 
For the analysis of secondary endpoints, the following analysis will be considered: 
Summary tables for differences of baseline compared to 6-week and baseline compared to 12-week post-
treatment of subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale will 
be displayed as mean difference, standard deviation and standard error.  The point level for each of these 
ordinal scale assessment tools will be put into consideration where applicable. 
 
Bar charts, pie chart, graphs or any other descriptive statistical displays indicating scores, percentages or 
proportions of Subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale 
will be used to analyse efficacy. 
 
All statistical tests that will be one-sided. The level of statistical significance for effectiveness analyses is 
5% (α = 0.05) for all tests of differences. Where appropriate, Paired t-test and/or Wilcoxon Signed-Ranks 
Test for Matched Pairs will be used to compare the evaluations score differences of baseline compared to 
6-week and baseline compared to 12-week post treatment assessment. Analysis of Covariance (ANCOVA) 
may also be used where appropriate.  
Subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale of all subjects 
who received at least one treatment of Venus Viva™ MD fractional RF device and for whom at least one 
valid post-baseline assessment was obtained will be analysed for these secondary endpoints. Multiple 
imputation method or modelling of available data may be used for missing data as appropriate. 
10.4.4 SAFETY ANALYSES 
The safety analysis will be done by analyzing spontaneous reports of adverse events (AE), subjects 
completed 10 cm discomfort/pain VAS and Tolerability Scale as well as analysis of immediate and short 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 32 of 40 
     1.0  
January 29th, 2021 
 
term response reports by the principal investigator from his/her observation/examination of the treated area. 
Appropriate Medical Dictionary for Regulatory Activities (MedDRA) code will be used to describe all 
spontaneously reported or other study related adverse events. 
Summaries of spontaneously reported or other study related adverse events will be presented as: 
o Number (%) of subjects with any AE, 
o Number (%) of subjects with any serious adverse events (SAE), 
o Number (%) of subjects permanently withdrawn from treatment due to AE 
Summaries of analysis of immediate and short-term response reports by the principal investigator 
examination will be displayed on a bar or pie chart as; 
o the overall frequency of subjects with each event (pain during treatment, hemorrhage, burn, 
erythema, edema, purpura) 
o Frequency of subjects with specific severity/intensity for each event using a 5 points scale: 1=none; 
2=trace; 3=moderate; 4=marked; 5=severe 
o The overall percentage or proportion of subject observed with marked or severe intensity of any 
event will be calculated and compared to those with none, trace or moderate severity/intensity with 
the aid of a bar or pie chart. 
The following will be considered for the analysis of 10 cm discomfort/pain VAS scores safety data: 
Summary table for differences of baseline and Visit 4 treatment 10 cm discomfort/pain VAS scores will be 
displayed as mean difference, standard deviation and standard error.  The 10 cm discomfort/pain VAS is a 
11-level (0 to 10) ordinal scale tool for assessing pain. 
 
Bar, pie charts or graphs indicating scores, percentages or proportions of subjects with Visit 4 treatment 
and baseline (Visit 2) VAS scores difference and Tolerability Scale will be used to analyse subjects’ 
tolerability of this treatment. 
 
All statistical tests will be one-sided. The level of statistical significance for effectiveness analyses is 5% 
(α = 0.05) for all tests of differences. Where appropriate, Paired t-test and/or Wilcoxon Signed-Ranks Test 
for Matched Pairs will be used to compare the difference between baseline and Visit 4 treatment VAS 
scores. 
The Paired t-test and/or Wilcoxon Signed-Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that: 
• 
The one-sided 95% confidence interval for the difference between the means excludes zero. 
• 
The two means are statistically significantly different at the 5% level (P < 0.05) one-sided. 
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t-test will 
be used to test expected safety endpoint; that is alternative hypothesis, Ha < 1.  
10.4.5 ADHERENCE AND RETENTION ANALYSES 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 33 of 40 
     1.0  
January 29th, 2021 
 
Adherence to the protocol will be assessed by calculating the number (%) subjects’ data for each endpoint 
assessment that is not provided in subjects Case Report Forms. This will be further analysed as per 
frequency of each endpoint data that is not available due to loss to follow-up, discontinuation of the 
intervention or any other reason. 
10.4.6  BASELINE DESCRIPTIVE STATISTICS 
Subjects baseline scores of all endpoints (GAIS, Subject Satisfaction Scale, Treatment Evaluation 
Questionnaire, VAS and Tolerability Scale) will be compared using descriptive statistics such as mean 
score, standard deviation, standard error, range and graphical presentations.  
10.4.7 PLANNED INTERIM ANALYSES  
 
No interim analysis is planned.   
 
10.4.7.1 
SAFETY REVIEW 
There will be no interim safety analysis during this study. However, this study may be temporarily 
suspended or prematurely terminated if there is sufficient reasonable cause. 
10.4.7.2 
EFFICACY REVIEW 
There will be no interim efficacy analysis during this study. However, this study may be temporarily 
suspended or prematurely terminated if there is sufficient reasonable cause. 
10.4.8 ADDITIONAL SUB-GROUP ANALYSES 
Primary or secondary endpoints may be further analyzed based on age, sex, race/ethnicity or other 
demographic characteristic(s). 
10.4.10 
TABULATION OF INDIVIDUAL RESPONSE DATA 
Individual participant data will be listed by measure and time point as appendix to the study report. 
10.5 
MEASURES TO MINIMIZE BIAS 
 
10.5.1 ENROLLMENT/ RANDOMIZATION/ MASKING PROCEDURES 
At screening, once a subject has signed the informed consent, and inclusion/exclusion criteria has been 
met, a subject number will be assigned. This unique identifier will be used throughout the entire study and 
will be entered in the subject's CRF and for each treatment. Subjects are randomized; this is an open-
label, baseline-controlled, evaluator-blind multi-center study. 
10.5.2 EVALUATION OF SUCCESS OF BLINDING  
Only the independent reviewers will be blinded. The treating physician and biostatistician or designated 
party (who conducts interim analysis) will not be blinded. 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 34 of 40 
     1.0  
January 29th, 2021 
 
11 
SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS 
Each participating site will maintain appropriate medical and research records for this trial, in compliance 
with ISO 14155:2011, and regulatory and institutional requirements for the protection of confidentiality 
of participants. Each site will permit authorized representatives of the study sponsor, ethics committee 
and/or regulatory agencies to examine (and when permitted by applicable law, to copy) clinical records 
for the purposes of quality assurance reviews, audits, and evaluation of the study safety, progress, and 
data validity.  
Source data are all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial. Examples of these original 
documents and data records include, but are not limited to, hospital records, clinical and office charts, 
laboratory notes, memoranda, participants' memory aids or evaluation checklists, pharmacy dispensing 
records, recorded audio tapes of counseling sessions, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, photographic 
negatives (where applicable), microfilm or magnetic media, x-rays, and participant files and records kept 
at the pharmacy, at the laboratories, and medico-technical departments involved in the clinical trial.  
It is acceptable to use CRFs as source documents. The following CRFs collected on no carbon required 
(NCR) paper will be source documents: 
• 
Subject self-reported VAS and Tolerability Scale, GAIS and Subject Satisfaction Scale 
The remainder of the data collected from other sources. 
It is not acceptable for the CRF to be the only record of a subject’s participation in the study. This is to 
ensure that anyone who would access the patient medical record has adequate knowledge that the patient 
is participating in a clinical trial. 
12 
QUALITY ASSURANCE AND QUALITY CONTROL 
Prior to any independent use of the Venus Viva™ MD device, study personnel, will receive proper 
training from the sponsor. Site personnel will be trained on the use of the device prior to study initiation 
at the site.  Additional training requirements will be discussed during study initiation and will include site 
responsibilities, and study documentation. In addition, the sponsor will provide protocol specific training 
for the site. The site will document which individual has been assigned to a specific task and will ensure 
that appropriate training has occurred for that task. 
Regular monitoring and an independent audit, if conducted, must be performed according to ISO 
14155:2011. See also Section 9, Clinical Monitoring. 
Quality control (QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated.  Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resolution. 
Monitors will verify that the clinical trial is conducted, and data are generated, documented (recorded), 
and reported in compliance with the protocol, GCP, and the applicable regulatory requirements. 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 35 of 40 
     1.0  
January 29th, 2021 
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory 
authorities. 
13 
ETHICS/PROTECTION OF HUMAN SUBJECTS  
 
13.1 
ETHICAL STANDARD  
The investigator will ensure that this study is conducted in full conformity with the latest version of the 
Declaration of Helsinki (2013), ISO 14155:2011 (Clinical investigation of medical devices for human 
subjects - Good clinical practice), FDA and any other applicable country’s ethical policy statement, 
whichever provides the higher level of protection to human subjects. 
13.2 
INSTITUTIONAL REVIEW BOARD  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the EC / IRB for review and approval. Approval of both the protocol and the consent form 
must be obtained before any participant is enrolled. Any amendment to the protocol will require review 
and approval by the EC / IRB before the changes are implemented to the study. All changes to the consent 
form will be EC / IRB approved; a determination will be made by Sponsor regarding whether previously 
consented participants need to be re-consented. 
13.3 
INFORMED CONSENT PROCESS  
 
13.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED 
TO PARTICIPANTS 
Informed consent is required for all subjects in a study.  In obtaining and documenting informed consent, 
the investigator should comply with applicable regulatory requirements and should adhere to ISO 
14155:2011 and to the latest version of the Declaration of Helsinki (2013).  Prior to the beginning of a 
trial, the investigator should have the EC / IRB's written approval for the protocol and the written 
informed consent forms(s) and any other written information to be provided to the participants.  Consent 
forms describing in detail the investigational medical device, study procedures, and risks are given to the 
participant and written documentation of informed consent is required prior to starting intervention with 
investigational medical device. 
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 
and continues throughout the individual’s study participation. Extensive discussion of risks and possible 
benefits of participation will be provided to the participants and their families.  Consent forms will be EC 
or IRB approved and the participant will be asked to read and review the document. The investigator will 
explain the research study to the participant and answer any questions that may arise. All participants will 
receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, potential 
risks of the study and their rights as research participants.  Participants will have the opportunity to 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 36 of 40 
     1.0  
January 29th, 2021 
 
carefully review the written consent form and ask questions prior to signing. The participants should have 
the opportunity to discuss the study with their surrogates or think about it prior to agreeing to participate. 
The participant will sign the informed consent document prior to any procedures being done specifically 
for the study. The participants may withdraw consent at any time throughout the course of the trial. A 
copy of the informed consent document will be given to the participants for their records. The rights and 
welfare of the participants will be protected by emphasizing to them that the quality of their medical care 
will not be adversely affected if they decline to participate in this study. 
13.4 
PARTICIPANT AND DATA CONFIDENTIALITY  
Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information relating to participants. Therefore, the study protocol, documentation, 
data, and all other information generated will be held in strict confidence. No information concerning the 
study or the data will be released to any unauthorized third party without prior written approval of the 
sponsor. 
The study monitor, other authorized representatives of the sponsor, representatives of the EC / IRB and 
Competent Authorities or device company supplying study product may inspect all documents and 
records required to be maintained by the investigator, including but not limited to, medical records 
(office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study site 
will permit access to such records. 
The study participant’s contact information will be securely stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by the sponsor, and any applicable regulations (refer to section 14.2 STUDY 
RECORDS RETENTION). 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 
be transmitted to and stored at the sponsor’s office. This will not include the participant’s contact or 
identifying information. Rather, individual participants and their research data will be identified by a 
unique study identification number. The study data entry and study management systems used by clinical 
sites and by sponsor’s research staff will be secured and password protected.  At the end of the study, all 
study databases will be de-identified and archived by the sponsor. 
13.4.1 RESEARCH USE OF STORED HUMAN SAMPLES,SPECIMENS OR DATA 
The investigator will store all data according to the local regulatory standards. Histological samples will 
be collected under this protocol to assess post-treatment changes in skin morphology.  
Access to stored samples will be limited to the principal investigator’s staff or designated lab and will be 
stored securely. Only investigators will have access to the samples. The sponsor will not have access to 
the samples, only the data generated from the samples. 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 37 of 40 
     1.0  
January 29th, 2021 
 
Disposition at the completion of the study: The investigator will store all the samples upto 2 years after 
study completion.  Study subjects who request destruction of samples will be notified of compliance with 
such request and all supporting details will be maintained for tracking. 
13.5 
FUTURE USE OF STORED SPECIMENS  
The histological samples will not be used for any other research other than this study. 
14 
DATA HANDLING AND RECORD KEEPING  
 
14.1 
DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
Principal Investigator.  The investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported. 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of 
data.  Black ink is required to ensure clarity of reproduced copies. When making changes or corrections, 
cross out the original entry with a single line, and initial and date the change.  DO NOT ERASE, 
OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL. 
Copies of the paper CRF will be provided for use as source documents and maintained for recording data 
for each participant enrolled in the study.  Data reported in the CRF derived from source documents 
should be consistent with the source documents or the discrepancies should be explained and captured in 
a progress note and maintained in the participant’s official study record.  Self-reported subject data and 
investigator CRF reported data recorded on the copy CRF page is permitted.  The original form will be 
collected by the sponsor and the copy will remain at the site. 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data from paper CRFs will be entered directly onto paper CRFs from the source documents and 
will be collected by the study sponsor. 
14.2 
STUDY RECORDS RETENTION  
Study documents, including copies of the paper CRFs, signed informed consent forms, photographs 
(where applicable), laboratory results, medical records, data clarification forms and regulatory documents, 
should be retained for a minimum period of 5 years after the end of the clinical investigation, or longer if 
required by local regulation. The investigator should take measures to prevent accidental or early 
destruction of the study related materials.  No records will be destroyed without the written consent of the 
sponsor, if applicable.  It is the responsibility of the sponsor to inform the investigator when these 
documents no longer need to be retained. 
14.3 
PROTOCOL DEVIATIONS  
A protocol deviation is any instance(s) of failure to follow, intentionally or unintentionally, the 
requirements of the Clinical Investigation Plan. Applicable definition follow: 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 38 of 40 
     1.0  
January 29th, 2021 
 
− 
Major deviation: CIP deviations that can have affected the rights, safety or well-being of the subject 
or the scientific integrity of the clinical investigation. 
− 
Minor deviation: CIP deviations that do NOT have affected the rights, safety or well-being of the 
subject or the scientific integrity of the clinical investigation. 
The noncompliance may be either on the part of the participant, the investigator, or the study site staff.  
As a result of deviations, corrective actions are to be developed by the site and implemented promptly. 
These practices are consistent with ISO 14155:2011: 
• 
4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
• 
5.1 Quality Assurance and Quality Control, section 5.1.1 
• 
5.20 Noncompliance, sections 5.20.1, and 5.20.2. 
Except in emergency situations, implementation of any clinical investigation plan change that affects 
patient safety, investigational scope, or the scientific quality of the study will not be permitted until all of 
the following conditions have been met: 
a. The Investigator, the Sponsor and Statistician have approved the protocol amendment and 
b. The responsible EC and Competent Authority has reviewed and approved the protocol change. 
Under emergency circumstances, deviations from the CIP to protect the rights, safety and well-being of 
human subjects may proceed without prior approval of the sponsor and the EC.  Such deviations shall be 
documented and reported to the sponsor and the EC as soon as possible.  
A corrective action will be taken: documenting the deviation (source document, log, CRF as relevant) 
including its reasons of occurrence and corrective actions to be taken to further avoid reoccurrence of it 
and properly reporting. The investigator as well as site personnel will be trained in order to avoid any 
major protocol deviation in the future. 
Failure to comply with this clinical investigation plan and/or EC, Competent Authorities, any local 
requirement will result in corrective actions and could result in the removal of the investigator from the 
study. 
It is the responsibility of the site to use continuous vigilance to identify and report deviations promptly to 
study sponsor and to EC (if required by local regulation).  All deviations must be addressed in study 
source documents.  The site PI/study staff is responsible for knowing and adhering to their EC 
requirements.  
14.4 
PUBLICATION AND DATA SHARING POLICY 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a 
clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any 
research project that prospectively assigns human subjects to intervention or concurrent comparison or 
control groups to study the cause-and-effect relationship between a medical intervention and a health 
outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, 
process-of-care changes, and the like.  Health outcomes include any biomedical or health-related 

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 39 of 40 
     1.0  
January 29th, 2021 
 
measures obtained in patients or participants and adverse events. The ICMJE policy, and the Section 801 
of the Food and Drug Administration Amendments Act of 2007, requires that all clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library 
of Medicine. Other biomedical journals are considering adopting similar policies.  The Declaration of 
Helsinki current revision (2013) states that every research study involving human subjects must be 
registered in a publicly accessible database before recruitment of the first subject (sec.35).  
The sponsor or its designee will register the VI1218 study into a publicly accessible database.  All data 
generated from this study are the property of Venus Concept Ltd and shall be held in strict confidence 
along with all information furnished by Venus Concept Ltd. 
Independent analysis and/or publication of these data by the Investigator or any member of his/her staff 
are not permitted without prior written consent of Venus Concept Ltd.  Written permission to the 
Investigator will be contingent on the review by Venus Concept Ltd of the statistical analysis and 
manuscript and will provide for nondisclosure of Venus Concept Ltd confidential or proprietary 
information. In all cases, the parties agree to submit all manuscripts or abstracts to all other parties at least 
60 days prior to submission. This will enable all parties to protect proprietary information and to provide 
comments based on information that may not yet be available to other parties. 
This policy might be overruled by other signed agreements made between the sponsor and investigators at 
a later date. 
15 
STUDY ADMINISTRATION 
 
15.1 
STUDY LEADERSHIP 
The study will be administered by the sponsor, Venus Concept Ltd. 
16 
CONFLICT OF INTEREST POLICY 
The independence of this study from any actual or perceived influence, such as by the device industry, is 
critical. Therefore, any actual conflict of interest of persons who have a role in the design, conduct, 
analysis, publication, or any aspect of this trial will be disclosed and managed.  Furthermore, persons who 
have a perceived conflict of interest will be required to have such conflicts managed in a way that is 
appropriate to their participation in the trial.  The sponsor will ensure that all study group members 
disclose all conflicts of interest and will establish a mechanism for the management of all reported 
dualities of interest. 
17  
LITERATURE REFERENCES  
 
1.  Simmons BJ, Griffith RD, Falto-Aizpurua LA, Nouri K. Use of radiofrequency in cosmetic 
dermatology: focus on nonablative treatment of acne scars. Clinical, Cosmetic and Investigational 
Dermatology. 2014;7:335–9.  

 
Version 1.0 
Protocol VI0121 
29th January 2021 
Venus Concept    
CONFIDENTIAL 
Page 40 of 40 
     1.0  
January 29th, 2021 
 
2.  O’Daniel TG. Multimodal management of atrophic acne scarring in the aging face. Aesthetic Plast 
Surg. 2011 Dec;35(6):1143–50.  
3.  Omi T, Sato S, Kaminaka C, Yamamoto Y, Kawana S, Naito Z. A Histological Study on the 
Treatment of Acne Scars with Fractional Radiofrequency: Preliminary Findings. Clin Exp Dermatol 
Res. 2014;5(1).  
4.  de Felipe I, Del Cueto SR, Pérez E, Redondo P. Adverse reactions after nonablative radiofrequency: 
follow-up of 290 patients. J Cosmet Dermatol. 2007 Sep;6(3):163–6.  
 
APPENDIX 
 
Version 
Date 
Significant Revisions